Emi Kurimoto

Title: Emi Kurimoto: Innovator in Cholinergic Modulation

Introduction

Emi Kurimoto is a prominent inventor based in Kanagawa, Japan. She has made significant contributions to the field of pharmacology, particularly in the development of methods for treating Alzheimer's disease. Her innovative approach focuses on reducing cholinergic side effects associated with muscarinic M1 receptor positive allosteric modulators.

Latest Patents

Emi Kurimoto holds 1 patent for her invention titled "Method for measuring alpha value of muscarinic M1 receptor positive allosteric modulators." This patent presents a useful and efficient screening method for identifying cholinergic muscarinic M1 receptor positive allosteric modulators (M1PAM) that minimize cholinergic side effects. The invention also outlines methods for treating Alzheimer's disease and reducing cholinergic side effects using M1PAM selected through her screening method.

Career Highlights

Emi Kurimoto is currently associated with Takeda Pharmaceutical Company Limited, where she continues to advance her research and development efforts. Her work is pivotal in the search for effective treatments for neurodegenerative diseases, showcasing her commitment to improving patient outcomes.

Collaborations

Emi collaborates with esteemed colleagues, including Haruhide Kimura and Yuu Sako, to further enhance the impact of her research. Their combined expertise contributes to the innovative solutions being developed in the field of pharmacology.

Conclusion

Emi Kurimoto's contributions to the field of pharmacology, particularly through her patent on muscarinic M1 receptor positive allosteric modulators, highlight her role as a leading inventor. Her work not only addresses critical health issues but also paves the way for future innovations in treatment methodologies.